Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatment of atherosclerosis and other disorders. The initiation of this trial does not trigger a milestone payment.

"We are very pleased with the progress of this collaboration investigating the therapeutic potential of niacin receptor agonists to treat atherosclerosis and other disorders. We are looking forward to the Phase 1 results and the continued progress of the program," said Jack Lief, Arena's President and Chief Executive Officer.

Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons.

About Atherosclerosis

Atherosclerosis is characterized by the collection of fatty material deposits, such as cholesterol, along artery walls. This fatty material thickens, hardens, and may eventually block the arteries, adversely affecting blood flow and increasing the risk of heart attack and stroke over time. The American Heart Association estimates that atherosclerosis accounts for nearly 75% of all deaths from cardiovascular disease. HDL cholesterol, commonly known as the "good" cholesterol, can help clear the fatty deposits from the walls of blood vessels and transport cholesterol to the liver for processing and removal from the body. Drugs that can influence the levels of HDL cholesterol, or "good" cholesterol, may potentially provide clinical benefits to patients by reducing the risk of heart attack and stroke. The niacin receptor, a G protein-coupled receptor, or GPCR, is believed to have potential in regulating plasma lipid profiles, including HDL.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic and other potential of niacin receptor agonists; the results of the Phase 1 clinical trial of a second generation niacin receptor agonist; the continuation and progress of the collaboration between Merck and Arena and the activities and program thereunder; the niacin receptor's potential in regulating plasma lipid profiles; the potential of drugs that influence HDL cholesterol to provide clinical benefits to patients; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward- looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... -- Alex,s Lemonade Stand Foundation (ALSF), a leading national childhood ... state-of-the-art bioinformatics lab, using ,big data, to advance the ... Liz Scott , co-executive director of ALSF and ... Washington, D.C. , hosted by Vice ... of pediatric cancer research and awareness. ...
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):